Could a common arthritis drug save Children's hearts?
NCT ID NCT07371689
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether the anti-inflammatory drug anakinra can help children with acute myocarditis (heart inflammation) recover heart function faster. About 110 children in intensive care will receive either anakinra or a placebo for 7 days, alongside standard care. The main goal is to see if more children achieve normal heart function within 3 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anakinra (Kineret), an anti-inflammatory drug
- What this could lead to
- If it works, this could provide a new treatment to quickly restore heart function in children with severe heart inflammation.
- What could go wrong
- This is an early-stage Phase 3 trial with only 110 participants. The drug may not improve recovery more than standard care, and side effects like infections are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC ACUTE MYOCARDITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bicêtre Hospital - APHP, Pediatric intensive care unit
Le Kremlin-Bicêtre, France, 94275, France